BIOTRONIK Blog Explore our latest insightful interviews and articles Image Blog Stories Filter and Search Filter by year - Any -20242023202220212020 Search 23 blog articles Image A Simplified Approach to Complex SFA PAD With the Oscar Peripheral Multifunctional Catheter Webinar Oscar Live Case - Zoom Link old See BIOTRONIK’s new Oscar peripheral multifunctional catheter in action with a live case streamed from the Vascular Center Arnsberg. Link will be updated soon! Image Blog BIOTRONIK Employees Donate Over 14,000 Euros to the Arche Berlin-Hellersdorf A Donation Ceremony Took Place at the Woermannkehre, on January 18, 2024 Image Blog The Effects of Air Pollution on Heart Health Higher quality of life, more biodiversity and a better climate – the advantages of green cities seem obvious. Green living – including breathing clean air – plays an especially crucial role for our heart health and overall well-being. On the occasion of World Environment Day, we looked at what effect air pollution has on heart health and what each of us can do to make our cities more livable. Image Blog Four Ways to Lower Your Atrial Fibrillation Risk Atrial Fibrillation Is the Most Common Type of Heart Arrhythmia and Affects About 30 Million People Worldwide. Image Blog How Love Benefits Your Heart Health Exploring the Science Behind Love's Cardiovascular Benefits Image Blog Improving Cardiovascular Health This International Women’s Day Image Blog How Much Exercise Is Enough for a Healthy Heart? Recent Studies Reveal Optimal Levels of Physical Activity for Cardiovascular Health Image Gold Standard for Two Decades: Why the Use of GoldTip is Still Unbeaten in Certain Ablation Procedures Image 60 Years of Saving Lives – How the BIOTRONIK Mission Continues Pagination Current page 1 Page 2 Page 3 Next page Next › Subscribe for our News You must have JavaScript enabled to use this form. Title Select TitleMsMrMXDrProf First name Last name Role Please select your roleHealthcare ProfessionalPatient or RelativeJournalistOther Email Phone Country/Region - Select -AfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua & BarbudaArgentinaArmeniaArubaAscension IslandAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBosnia & HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBritish Virgin IslandsBruneiBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCanary IslandsCape VerdeCaribbean NetherlandsCayman IslandsCentral African RepublicCeuta & MelillaChadChileChinaChristmas IslandClipperton IslandCocos (Keeling) IslandsColombiaComorosCongo - BrazzavilleCongo - KinshasaCook IslandsCosta RicaCroatiaCubaCuraçaoCyprusCzechiaCôte d’IvoireDenmarkDiego GarciaDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatiniEthiopiaFalkland IslandsFaroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard & McDonald IslandsHondurasHong Kong SAR ChinaHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKosovoKuwaitKyrgyzstanLaosLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacao SAR ChinaMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmar (Burma)NamibiaNauruNepalNetherlandsNetherlands AntillesNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorthern Mariana IslandsNorth KoreaNorth MacedoniaNorwayOmanOutlying OceaniaPakistanPalauPalestinian TerritoriesPanamaPapua New GuineaParaguayPeruPhilippinesPitcairn IslandsPolandPortugalPuerto RicoQatarRomaniaRussiaRwandaRéunionSamoaSan MarinoSarkSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint MaartenSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia & South Sandwich IslandsSouth KoreaSouth SudanSpainSri LankaSt. BarthélemySt. HelenaSt. Kitts & NevisSt. LuciaSt. MartinSt. Pierre & MiquelonSt. Vincent & GrenadinesSudanSurinameSvalbard & Jan MayenSwedenSwitzerlandSyriaSão Tomé & PríncipeTaiwanTajikistanTanzaniaThailandTimor-LesteTogoTokelauTongaTrinidad & TobagoTristan da CunhaTunisiaTurkmenistanTurks & Caicos IslandsTuvaluTürkiyeU.S. Outlying IslandsU.S. Virgin IslandsUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVatican CityVenezuelaVietnamWallis & FutunaWestern SaharaYemenZambiaZimbabweÅland Islands Topic Please select a topicProductsPatientsHealthcare Professionals I prefer to be contacted by Phone Email Message *Fields are mandatory. Latest Press Releases Show all press releases Image COPENHAGEN, Denmark Press Release BIOLUX P-III BENELUX All-Comers Registry Demonstrates Safety and Efficacy of BIOTRONIK’s Drug-Coated Balloon in Isolated Popliteal Lesions at 24 Months BIOTRONIK announced the two-year-results from the BIOLUX P-III BENELUX all-comers registry, presented by Principal Investigator Prof. Frank Vermassen at CIRSE 2023 in Copenhagen, Denmark. 1 The prospective, international, multicenter post-market registry evaluated the safety and efficacy of the Passeo ®-18 Lux ® drug-coated balloon (DCB) catheter in isolated popliteal artery lesions. This indication is considered a difficult vessel bed to treat due to its biomechanical constraints that usually preclude the placement of stents. BIOLUX P-III BENELUX registry enrolled 99 patients in Belgium, the Image BÜLACH, Switzerland Press Release Two-Year BIOPACT Randomized Controlled Trial (RCT) Analysis Demonstrates “Persistent Excellence” for Low-Profile Passeo-18 Lux DCB BIOTRONIK announced the presentation of two-year results from the investigator-initiated BIOPACT RCT by Principal Investigator Dr. Koen Deloose at the Paris Vascular Insights 2023 congress. The randomized controlled non-inferiority trial evaluated the safety and efficacy of the Passeo®-18 Lux® drug-coated balloon (DCB) catheter compared to the In.Pact Admiral DCB (Medtronic), and showed excellent results for both balloons through 24 months. 1 The prospective, multicenter, core-lab adjudicated non-inferiority trial enrolled 302 patients in Austria, Belgium, France and Switzerland with Image AMSTERDAM, The Netherlands Press Release 12-Month-Data of BIOFLOW-DAPT Study Show Positive Results for Orsiro Mission DES With Short DAPT BIOFLOW-DAPT one-year-data demonstrated non-inferiority and a good safety profile for the Orsiro ® Mission drug-eluting stent (DES) compared to Resolute Onyx DES (p<0.0001) in patients at high risk of bleeding receiving short dual antiplatelet therapy (DAPT). Prof. Marco Valgimigli presented the novel data in a late-breaking trial session at the European Society of Cardiology’s (ESC) Congress in Amsterdam. The results were published simultaneously in Circulation. BIOFLOW-DAPT is a prospective, multi-center, international, two-arm randomized controlled clinical study to assess the safety of one Press Contact Corporate Public Relations & Communications press@biotronik.com +49 (0) 30 68905 1414 Get in contact
Image A Simplified Approach to Complex SFA PAD With the Oscar Peripheral Multifunctional Catheter Webinar Oscar Live Case - Zoom Link old See BIOTRONIK’s new Oscar peripheral multifunctional catheter in action with a live case streamed from the Vascular Center Arnsberg. Link will be updated soon!
Image A Simplified Approach to Complex SFA PAD With the Oscar Peripheral Multifunctional Catheter Webinar Oscar Live Case - Zoom Link old See BIOTRONIK’s new Oscar peripheral multifunctional catheter in action with a live case streamed from the Vascular Center Arnsberg. Link will be updated soon!
Image Blog BIOTRONIK Employees Donate Over 14,000 Euros to the Arche Berlin-Hellersdorf A Donation Ceremony Took Place at the Woermannkehre, on January 18, 2024
Image Blog BIOTRONIK Employees Donate Over 14,000 Euros to the Arche Berlin-Hellersdorf A Donation Ceremony Took Place at the Woermannkehre, on January 18, 2024
Image Blog The Effects of Air Pollution on Heart Health Higher quality of life, more biodiversity and a better climate – the advantages of green cities seem obvious. Green living – including breathing clean air – plays an especially crucial role for our heart health and overall well-being. On the occasion of World Environment Day, we looked at what effect air pollution has on heart health and what each of us can do to make our cities more livable.
Image Blog The Effects of Air Pollution on Heart Health Higher quality of life, more biodiversity and a better climate – the advantages of green cities seem obvious. Green living – including breathing clean air – plays an especially crucial role for our heart health and overall well-being. On the occasion of World Environment Day, we looked at what effect air pollution has on heart health and what each of us can do to make our cities more livable.
Image Blog Four Ways to Lower Your Atrial Fibrillation Risk Atrial Fibrillation Is the Most Common Type of Heart Arrhythmia and Affects About 30 Million People Worldwide.
Image Blog Four Ways to Lower Your Atrial Fibrillation Risk Atrial Fibrillation Is the Most Common Type of Heart Arrhythmia and Affects About 30 Million People Worldwide.
Image Blog How Love Benefits Your Heart Health Exploring the Science Behind Love's Cardiovascular Benefits
Image Blog How Love Benefits Your Heart Health Exploring the Science Behind Love's Cardiovascular Benefits
Image Blog How Much Exercise Is Enough for a Healthy Heart? Recent Studies Reveal Optimal Levels of Physical Activity for Cardiovascular Health
Image Blog How Much Exercise Is Enough for a Healthy Heart? Recent Studies Reveal Optimal Levels of Physical Activity for Cardiovascular Health
Image Gold Standard for Two Decades: Why the Use of GoldTip is Still Unbeaten in Certain Ablation Procedures
Image Gold Standard for Two Decades: Why the Use of GoldTip is Still Unbeaten in Certain Ablation Procedures
Image COPENHAGEN, Denmark Press Release BIOLUX P-III BENELUX All-Comers Registry Demonstrates Safety and Efficacy of BIOTRONIK’s Drug-Coated Balloon in Isolated Popliteal Lesions at 24 Months BIOTRONIK announced the two-year-results from the BIOLUX P-III BENELUX all-comers registry, presented by Principal Investigator Prof. Frank Vermassen at CIRSE 2023 in Copenhagen, Denmark. 1 The prospective, international, multicenter post-market registry evaluated the safety and efficacy of the Passeo ®-18 Lux ® drug-coated balloon (DCB) catheter in isolated popliteal artery lesions. This indication is considered a difficult vessel bed to treat due to its biomechanical constraints that usually preclude the placement of stents. BIOLUX P-III BENELUX registry enrolled 99 patients in Belgium, the
Image COPENHAGEN, Denmark Press Release BIOLUX P-III BENELUX All-Comers Registry Demonstrates Safety and Efficacy of BIOTRONIK’s Drug-Coated Balloon in Isolated Popliteal Lesions at 24 Months BIOTRONIK announced the two-year-results from the BIOLUX P-III BENELUX all-comers registry, presented by Principal Investigator Prof. Frank Vermassen at CIRSE 2023 in Copenhagen, Denmark. 1 The prospective, international, multicenter post-market registry evaluated the safety and efficacy of the Passeo ®-18 Lux ® drug-coated balloon (DCB) catheter in isolated popliteal artery lesions. This indication is considered a difficult vessel bed to treat due to its biomechanical constraints that usually preclude the placement of stents. BIOLUX P-III BENELUX registry enrolled 99 patients in Belgium, the
Image BÜLACH, Switzerland Press Release Two-Year BIOPACT Randomized Controlled Trial (RCT) Analysis Demonstrates “Persistent Excellence” for Low-Profile Passeo-18 Lux DCB BIOTRONIK announced the presentation of two-year results from the investigator-initiated BIOPACT RCT by Principal Investigator Dr. Koen Deloose at the Paris Vascular Insights 2023 congress. The randomized controlled non-inferiority trial evaluated the safety and efficacy of the Passeo®-18 Lux® drug-coated balloon (DCB) catheter compared to the In.Pact Admiral DCB (Medtronic), and showed excellent results for both balloons through 24 months. 1 The prospective, multicenter, core-lab adjudicated non-inferiority trial enrolled 302 patients in Austria, Belgium, France and Switzerland with
Image BÜLACH, Switzerland Press Release Two-Year BIOPACT Randomized Controlled Trial (RCT) Analysis Demonstrates “Persistent Excellence” for Low-Profile Passeo-18 Lux DCB BIOTRONIK announced the presentation of two-year results from the investigator-initiated BIOPACT RCT by Principal Investigator Dr. Koen Deloose at the Paris Vascular Insights 2023 congress. The randomized controlled non-inferiority trial evaluated the safety and efficacy of the Passeo®-18 Lux® drug-coated balloon (DCB) catheter compared to the In.Pact Admiral DCB (Medtronic), and showed excellent results for both balloons through 24 months. 1 The prospective, multicenter, core-lab adjudicated non-inferiority trial enrolled 302 patients in Austria, Belgium, France and Switzerland with
Image AMSTERDAM, The Netherlands Press Release 12-Month-Data of BIOFLOW-DAPT Study Show Positive Results for Orsiro Mission DES With Short DAPT BIOFLOW-DAPT one-year-data demonstrated non-inferiority and a good safety profile for the Orsiro ® Mission drug-eluting stent (DES) compared to Resolute Onyx DES (p<0.0001) in patients at high risk of bleeding receiving short dual antiplatelet therapy (DAPT). Prof. Marco Valgimigli presented the novel data in a late-breaking trial session at the European Society of Cardiology’s (ESC) Congress in Amsterdam. The results were published simultaneously in Circulation. BIOFLOW-DAPT is a prospective, multi-center, international, two-arm randomized controlled clinical study to assess the safety of one
Image AMSTERDAM, The Netherlands Press Release 12-Month-Data of BIOFLOW-DAPT Study Show Positive Results for Orsiro Mission DES With Short DAPT BIOFLOW-DAPT one-year-data demonstrated non-inferiority and a good safety profile for the Orsiro ® Mission drug-eluting stent (DES) compared to Resolute Onyx DES (p<0.0001) in patients at high risk of bleeding receiving short dual antiplatelet therapy (DAPT). Prof. Marco Valgimigli presented the novel data in a late-breaking trial session at the European Society of Cardiology’s (ESC) Congress in Amsterdam. The results were published simultaneously in Circulation. BIOFLOW-DAPT is a prospective, multi-center, international, two-arm randomized controlled clinical study to assess the safety of one